Hepatitis Monthly

Published by: Kowsar

Association of Tumor Necrosis Factor-alpha Polymorphisms and Risk of Coronary Artery Disease in Patients With Non-alcoholic Fatty Liver Disease

Yuting Cheng 1 , Baiquan An 1 , Man Jiang 2 , Yongning Xin 2 , * and Shiying Xuan 1
Authors Information
1 Department of Gastroenterology, Qingdao Medical College; Nanjing Medical University, Qingdao, China
2 Department of Gastroenterology, Qingdao Municipal Hospital, Qingdao Medical College, Nanjing Medical University, Qingdao, China
Article information
  • Hepatitis Monthly: March 01, 2015, 15 (3); e26818
  • Published Online: March 31, 2015
  • Article Type: Research Article
  • Received: January 14, 2015
  • Revised: February 2, 2015
  • Accepted: February 14, 2015
  • DOI: 10.5812/hepatmon.26818

To Cite: Cheng Y, An B, Jiang M, Xin Y, Xuan S. Association of Tumor Necrosis Factor-alpha Polymorphisms and Risk of Coronary Artery Disease in Patients With Non-alcoholic Fatty Liver Disease, Hepat Mon. 2015 ; 15(3):e26818. doi: 10.5812/hepatmon.26818.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6): 1387-95[DOI][PubMed]
  • 2. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011; 26 Suppl 1: 163-72[DOI][PubMed]
  • 3. Abangah G, Yousefi A, Asadollahi R, Veisani Y, Rahimifar P, Alizadeh S. Correlation of Body Mass Index and Serum Parameters With Ultrasonographic Grade of Fatty Change in Non-alcoholic Fatty Liver Disease. Iran Red Crescent Med J. 2014; 16(1)[DOI][PubMed]
  • 4. Jafarian A, Ebrahimi A, Azmoudeh Ardalan F, Dashti H, Rahimi M, Salehi M, et al. NAFLD Prevalence in a Young Cadaveric Organ Donor Population. Hepat Mon. 2014; 14(10)[DOI][PubMed]
  • 5. Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol. 2011; 17(26): 3082-91[DOI][PubMed]
  • 6. Bieghs V, Rensen PC, Hofker MH, Shiri-Sverdlov R. NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages. Atherosclerosis. 2012; 220(2): 287-93[DOI][PubMed]
  • 7. Sookoian S, Gianotti TF, Rosselli MS, Burgueno AL, Castano GO, Pirola CJ. Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis. 2011; 218(2): 378-85[DOI][PubMed]
  • 8. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010; 363(14): 1341-50[DOI][PubMed]
  • 9. Zhang H, Chen L, Xin Y, Lou Y, Liu Y, Xuan S. Apolipoprotein c3 gene polymorphisms are not a risk factor for developing non-alcoholic Fatty liver disease: a meta-analysis. Hepat Mon. 2014; 14(10)[DOI][PubMed]
  • 10. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996; 271(5249): 665-8[PubMed]
  • 11. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999; 18(6): 353-8[DOI][PubMed]
  • 12. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999; 84(5): 1513-7[DOI][PubMed]
  • 13. Balci SO, Col-Araz N, Baspinar O, Sever T, Balat A, Pehlivan S. Cytokine Gene Polymorphisms in Childhood Dilated Cardiomyopathy: Interferon- gamma, Tumor Necrosis Factor-alpha and Transforming Growth Factor - beta 1 Genes Are Associated with the Disease in Turkish Patients. Iran J Pediatr. 2013; 23(5): 603-4[PubMed]
  • 14. Boehm J, Hauner K, Grammer J, Dietrich W, Wagenpfeil S, Braun S, et al. Tumor necrosis factor-alpha -863 C/A promoter polymorphism affects the inflammatory response after cardiac surgery. Eur J Cardiothorac Surg. 2011; 40(1)-4[DOI][PubMed]
  • 15. Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun. 2004; 5(5): 315-29[DOI][PubMed]
  • 16. Elahi MM, Asotra K, Matata BM, Mastana SS. Tumor necrosis factor alpha -308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta. 2009; 1792(3): 163-72[PubMed]
  • 17. Anoosheh S, Farnia P, Kargar M. Association between TNF-Alpha (-857) Gene Polymorphism and Susceptibility to Tuberculosis. Iran Red Crescent Med J. 2011; 13(4): 243-8[PubMed]
  • 18. Naderi M, Yaghootkar H, Tara F, Tavakkol Afshari J, Farid Hosseini R, Ghayour Mobarhan M, et al. Tumor necrosis factor-alpha polymorphism at position -238 in preeclampsia. Iran Red Crescent Med J. 2014; 16(1)[DOI][PubMed]
  • 19. Hu ZW, Luo HB, Xu YM, Guo JW, Deng XL, Tong YW, et al. Tumor necrosis factor--alpha gene promoter polymorphisms in Chinese patients with nonalcoholic fatty liver diseases. Acta Gastroenterol Belg. 2009; 72(2): 215-21[PubMed]
  • 20. Huang J, Li YY, Zhou YJ. [Association between tumor necrosis factor-alpha gene polymorphism and insulin resistance in nonalcoholic fatty liver disease]. Zhonghua Gan Zang Bing Za Zhi. 2006; 14(8): 613-5[PubMed]
  • 21. Zhou YJ, Li YY, Nie YQ, Yang H, Zhan Q, Huang J, et al. Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. J Gastroenterol Hepatol. 2010; 25(4): 772-7[DOI][PubMed]
  • 22. Wang JK, Feng ZW, Li YC, Li QY, Tao XY. Association of tumor necrosis factor-alpha gene promoter polymorphism at sites -308 and -238 with non-alcoholic fatty liver disease: a meta-analysis. J Gastroenterol Hepatol. 2012; 27(4): 670-6[DOI][PubMed]
  • 23. Yamada Y, Ichihara S, Izawa H, Tanaka M, Yokota M. Genetic risk for coronary artery disease in individuals with or without type 2 diabetes. Mol Genet Metab. 2004; 81(4): 282-90[DOI][PubMed]
  • 24. Tokushige K, Takakura M, Tsuchiya-Matsushita N, Taniai M, Hashimoto E, Shiratori K. Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis. J Hepatol. 2007; 46(6): 1104-10[DOI][PubMed]
  • 25. Cho HC, Yu G, Lee MY, Kim HS, Shin DH, Kim YN. TNF-alpha polymorphisms and coronary artery disease: association study in the Korean population. Cytokine. 2013; 62(1): 104-9[DOI][PubMed]
  • 26. Vendrell J, Fernandez-Real JM, Gutierrez C, Zamora A, Simon I, Bardaji A, et al. A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis. 2003; 167(2): 257-64[PubMed]
  • 27. Allen RA, Lee EM, Roberts DH, Park BK, Pirmohamed M. Polymorphisms in the TNF-alpha and TNF-receptor genes in patients with coronary artery disease. Eur J Clin Invest. 2001; 31(10): 843-51[PubMed]
  • 28. Herrmann SM, Ricard S, Nicaud V, Mallet C, Arveiler D, Evans A, et al. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur J Clin Invest. 1998; 28(1): 59-66[PubMed]
  • 29. Wang XL, Oosterhof J. Tumour necrosis factor alpha G-308-->A polymorphism and risk for coronary artery disease. Clin Sci (Lond). 2000; 98(4): 435-7[PubMed]
  • 30. Keso T, Perola M, Laippala P, Ilveskoski E, Kunnas TA, Mikkelsson J, et al. Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis. 2001; 154(3): 691-7[PubMed]
  • 31. Chu H, Yang J, Mi S, Bhuyan SS, Li J, Zhong L, et al. Tumor necrosis factor-alpha G-308 A polymorphism and risk of coronary heart disease and myocardial infarction: A case-control study and meta-analysis. J Cardiovasc Dis Res. 2012; 3(2): 84-90[DOI][PubMed]
  • 32. Rickham PP. Human Experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. Br Med J. 1964; 2(5402): 177[PubMed]
  • 33. Jian-gao F, Chinese Liver Disease A. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi. 2010; 18(3): 163-6[PubMed]
  • 34. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab. 2007; 92(9): 3490-7[DOI][PubMed]
  • 35. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992; 10: 411-52[DOI][PubMed]
  • 36. Beutler B. TNF, immunity and inflammatory disease: lessons of the past decade. J Investig Med. 1995; 43(3): 227-35[PubMed]
  • 37. Shin KC, Chung JH, Lee KH. Effects of TNF-alpha and leptin on weight loss in patients with stable chronic obstructive pulmonary disease. Korean J Intern Med. 2007; 22(4): 249-55[PubMed]
  • 38. Feingold KR, Serio MK, Adi S, Moser AH, Grunfeld C. Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology. 1989; 124(5): 2336-42[DOI][PubMed]
  • 39. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes. 1992; 41 Suppl 2: 97-101[PubMed]
  • 40. Morin CL, Schlaepfer IR, Eckel RH. Tumor necrosis factor-alpha eliminates binding of NF-Y and an octamer-binding protein to the lipoprotein lipase promoter in 3T3-L1 adipocytes. J Clin Invest. 1995; 95(4): 1684-9[DOI][PubMed]
  • 41. Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002; 122(2): 274-80[PubMed]
  • 42. Park SH, Koo HJ, Sung YY, Kim HK. The protective effect of Prunella vulgaris ethanol extract against vascular inflammation in TNF-alpha-stimulated human aortic smooth muscle cells. BMB Rep. 2013; 46(7): 352-7[PubMed]
  • 43. Savic-Radojevic A, Radovanovic S, Pekmezovic T, Pljesa-Ercegovac M, Simic D, Djukic T, et al. The role of serum VCAM-1 and TNF-alpha as predictors of mortality and morbidity in patients with chronic heart failure. J Clin Lab Anal. 2013; 27(2): 105-12[DOI][PubMed]
  • 44. Angel K, Provan SA, Fagerhol MK, Mowinckel P, Kvien TK, Atar D. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am J Hypertens. 2012; 25(6): 644-50[DOI][PubMed]
  • 45. Razavizade M, Jamali R, Arj A, Talari H. Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2012; 11(5): 513-20[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments